Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inositol polyphosphate-5-phosphatase A (INPP5A) is a membrane-associated phosphatase that catalyzes the dephosphorylation of inositol 1,4,5-trisphosphate (IP3) to inositol 1,4-bisphosphate and inositol 1,3,4,5-tetrakisphosphate to inositol 1,3,4-trisphosphate. This activity regulates intracellular calcium mobilization by controlling IP3 levels, a key second messenger in many signaling pathways. INPP5A is essential for the survival of certain neuronal populations and is selectively required for the viability of GNAQ/11-mutant uveal melanoma cells, making it a potential cancer therapeutic target. Genetic deficiency or dysfunction is associated with spinocerebellar ataxia and neurodegenerative disease risk. No approved drugs directly target INPP5A and any therapeutic inhibition would require careful monitoring for potential neurological side effects due to its role in the central nervous system.
Inhibition of INPP5A synthetic-lethal in GNAQ/11-mutant uveal melanoma (preclinical)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inositol polyphosphate-5-phosphatase A (INPP5A).